Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - NINTEDANIB ESILATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

VOLUNTARY ANNOUNCEMENT - NINTEDANIB ESILATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

January 02, 2026

a260102_00.png

Previous: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS

Next: VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR DUOENYI (IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION) OBTAINS MARKETING APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat